Cybin Inc
CYBN6.000USD
0.000
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
138.20MCap. mercado
PérdidaP/E TTM
Más Datos de Cybin Inc Compañía
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Información de la empresa
Símbolo de cotizaciónCYBN
Nombre de la empresaCybin Inc
Fecha de salida a bolsaJan 05, 2018
Director ejecutivoMr. Eric How-Lun So
Número de empleados50
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 05
Dirección100 King Street West
CiudadTORONTO
Bolsa de valoresAequitas NEO-L
PaísCanada
Código postalM5X 1C9
Teléfono19087648385
Sitio Webhttps://www.cybin.com
Símbolo de cotizaciónCYBN
Fecha de salida a bolsaJan 05, 2018
Director ejecutivoMr. Eric How-Lun So
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
405.35K
+0.54%
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President, Interim Chief Executive Officer
Executive Chairman of the Board, President, Interim Chief Executive Officer
311.12K
-97.37%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Mr. Greg Cavers
Mr. Greg Cavers
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mark Lawson
Mr. Mark Lawson
Independent Director
Independent Director
--
--
Mr. Aaron Bartlone
Mr. Aaron Bartlone
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Eric Hoskins
Dr. Eric Hoskins
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
405.35K
+0.54%
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President, Interim Chief Executive Officer
Executive Chairman of the Board, President, Interim Chief Executive Officer
311.12K
-97.37%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 3 de sep
Actualizado: mié., 3 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Nivorozhkin (Alex)
20.85%
Tang Capital Management, LLC
7.27%
Point72 Asset Management, L.P.
6.38%
Deep Track Capital LP
6.07%
Global X Investments Canada Inc.
5.32%
Otro
54.12%
Accionistas
Accionistas
Proporción
Nivorozhkin (Alex)
20.85%
Tang Capital Management, LLC
7.27%
Point72 Asset Management, L.P.
6.38%
Deep Track Capital LP
6.07%
Global X Investments Canada Inc.
5.32%
Otro
54.12%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
34.68%
Hedge Fund
25.34%
Investment Advisor
7.15%
Investment Advisor/Hedge Fund
5.63%
Private Equity
0.45%
Research Firm
0.35%
Bank and Trust
0.06%
Otro
26.34%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
203
58.05M
152.46%
-77.16M
2025Q1
209
57.54M
286.29%
-78.15M
2024Q4
205
59.72M
283.54%
-81.34M
2024Q3
197
62.29M
285.74%
-324.75M
2024Q2
204
344.93M
166.65%
-48.46M
2024Q1
195
368.84M
163.99%
+249.67M
2023Q4
177
108.66M
110.45%
+25.70M
2023Q3
166
58.71M
23.51%
+14.44M
2023Q2
156
50.00M
26.24%
+942.60K
2023Q1
152
52.80M
27.84%
+4.58M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Nivorozhkin (Alex)
5.25M
24.3%
+280.74K
+5.65%
Mar 31, 2024
Tang Capital Management, LLC
1.83M
8.47%
+500.00K
+37.59%
Mar 31, 2025
Point72 Asset Management, L.P.
1.33M
6.14%
+508.22K
+62.13%
May 20, 2025
Deep Track Capital LP
1.53M
7.08%
--
--
Mar 31, 2025
Global X Investments Canada Inc.
1.34M
6.2%
-213.08K
-13.73%
Feb 29, 2024
Tziras (George)
1.29M
5.99%
--
--
Jul 24, 2024
Bartlone (Aaron Frank)
901.07K
4.17%
+200.00K
+28.53%
Jun 28, 2024
Rosalind Advisors, Inc.
810.92K
3.75%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
734.39K
3.4%
+1.00
+0.00%
Mar 31, 2025
Fahel (Gabriel)
287.70K
1.33%
+700.00
+0.24%
Mar 31, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Fecha
Tipo
Relación
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
